[go: up one dir, main page]

ES2075900T3 - Composiciones estables de vacuna que contienen interleucinas. - Google Patents

Composiciones estables de vacuna que contienen interleucinas.

Info

Publication number
ES2075900T3
ES2075900T3 ES90911344T ES90911344T ES2075900T3 ES 2075900 T3 ES2075900 T3 ES 2075900T3 ES 90911344 T ES90911344 T ES 90911344T ES 90911344 T ES90911344 T ES 90911344T ES 2075900 T3 ES2075900 T3 ES 2075900T3
Authority
ES
Spain
Prior art keywords
vaccine compositions
compositions containing
interleukin
mineral
interleukins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911344T
Other languages
English (en)
Inventor
Subramonia Pillai
Garvin Bixler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2075900T3 publication Critical patent/ES2075900T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTA INVENCION DESCRIBE COMPOSICIONES DE VACUNAS CONTENIENDO INTERLEUCINAS , COMPRENDIENDO UNA MEZCLA DE ANTIGENO Y UNA CANTIDAD ADYUVANTE DE UNA INTERLEUCINA ABSORVIDA EN UN MINERAL EN SUSPENSION Y UN PRESERVATIVO. PREFERENTEMENTE, EL MINERAL ES ALUMINIO. LA INTERLEUCINA PUEDE MODULAR LA RESPUESTA INMUNOPROTECTORA A UN ANTIGENO, MIENTRAS QUE EL MINERAL ESTABILIZA LA ACTIVIDAD BIOLOGICA DE LA INTERLEUCINA.
ES90911344T 1989-07-14 1990-07-16 Composiciones estables de vacuna que contienen interleucinas. Expired - Lifetime ES2075900T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14

Publications (1)

Publication Number Publication Date
ES2075900T3 true ES2075900T3 (es) 1995-10-16

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911344T Expired - Lifetime ES2075900T3 (es) 1989-07-14 1990-07-16 Composiciones estables de vacuna que contienen interleucinas.

Country Status (12)

Country Link
EP (1) EP0482076B1 (es)
JP (2) JP3485184B2 (es)
KR (1) KR0177179B1 (es)
AT (1) ATE121629T1 (es)
AU (1) AU648509B2 (es)
CA (1) CA2063587C (es)
DE (1) DE69018990T2 (es)
DK (1) DK0482076T3 (es)
ES (1) ES2075900T3 (es)
FI (1) FI104233B (es)
NO (1) NO301577B1 (es)
WO (1) WO1991001143A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
DK0563254T3 (da) * 1990-12-19 1996-02-12 Schering Corp Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
FI934866L (fi) * 1991-05-13 1993-11-12 Univ California Liposomala polysackaridvacciner
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
WO1994003202A1 (en) * 1992-08-10 1994-02-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Interleukin-4 stimulated t lymphocyte cell death
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO1996007102A1 (en) * 1994-09-01 1996-03-07 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
EP1015026B1 (en) * 1996-05-31 2006-05-10 National University of Ireland, Maynooth Il-12 as an adjuvant for bordetella pertussis vaccines
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU1813701A (en) 1999-12-03 2001-06-12 Celltech Chiroscience Limited Interleukin-1 muteins useful as vaccine adjuvants
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP1928418B1 (en) * 2005-09-30 2011-12-21 Lipoxen Technologies Limited Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
BRPI0713426A2 (pt) 2006-06-14 2012-10-09 Macrogenics Inc métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
EP2925297B1 (en) * 2012-11-02 2017-06-21 CyTuVax Composition comprising cytokine macro-aggregates
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
CA3119341A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
JP2023512657A (ja) 2020-02-05 2023-03-28 ワシントン・ユニバーシティ Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
IL302482A (en) 2020-11-05 2023-06-01 Neoimmunetech Inc Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
JP2025501238A (ja) 2021-12-30 2025-01-17 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とｖｅｇｆアンタゴニストの併用による腫瘍の治療方法
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
KR0177179B1 (ko) 1999-03-20
DK0482076T3 (da) 1995-07-17
NO301577B1 (no) 1997-11-17
NO920161L (no) 1992-03-05
JP2004002463A (ja) 2004-01-08
FI920132A0 (fi) 1992-01-13
CA2063587C (en) 2005-08-30
ATE121629T1 (de) 1995-05-15
EP0482076B1 (en) 1995-04-26
FI104233B1 (fi) 1999-12-15
NO920161D0 (no) 1992-01-13
AU648509B2 (en) 1994-04-28
EP0482076A1 (en) 1992-04-29
DE69018990D1 (de) 1995-06-01
CA2063587A1 (en) 1991-01-15
WO1991001143A1 (en) 1991-02-07
AU6050090A (en) 1991-02-22
FI104233B (fi) 1999-12-15
JP3485184B2 (ja) 2004-01-13
DE69018990T2 (de) 1995-12-14
KR920703103A (ko) 1992-12-17
JPH04506663A (ja) 1992-11-19

Similar Documents

Publication Publication Date Title
ES2075900T3 (es) Composiciones estables de vacuna que contienen interleucinas.
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
ES2111031T3 (es) Uso de preparaciones que contienen anticuerpos para la inmunosupresion.
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
NO943920D0 (no) Vaksineadjuvans
DE3370482D1 (en) Substituted 8-phenylxanthines
MX9803290A (es) Composiciones de la vacuna influenza.
DE3482907D1 (de) Verwendung des diterpen-derivates forskolin zur immunstimulation.
ES2109254T3 (es) Proteinas antigenas y vacunas que las contienen para la prevencion de cocidiosis.
ES521422A0 (es) Procedimiento para la obtencion de derivados de carboxilamida n-glicosilados.
IL90446A0 (en) Zinc-compatible silica for dentrifices,processes for the preparation thereof and dentrifices containing the same
DE3582272D1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
ATE275421T1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
DE69427824D1 (de) Impfstoffe bestehend aus protein- oder peptid-"cochleaten" und deren verwendung zur immunisierung
ZA817896B (en) Novel d-homosteroids
KR900005986A (ko) 항원용액중의 보조제로서 수산화아연 또는 수산화철의 용도, 및 이러한 보조제를 함유하는 항원용액
ES2096727T3 (es) Productos cosmeticos y farmaceuticos que contienen extensinas.
GB2227936A (en) Vaccine against brucella abortus
GR1000881B (el) Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
DE59004836D1 (de) Eliminierung von aktivierten lymphozyten.
IT8049346A0 (it) Composizione antigene relativo vaccino e procedimento di produzione

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 482076

Country of ref document: ES